{"id":457164,"date":"2021-03-15T07:00:37","date_gmt":"2021-03-15T11:00:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457164"},"modified":"2021-03-15T07:00:37","modified_gmt":"2021-03-15T11:00:37","slug":"atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/","title":{"rendered":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting"},"content":{"rendered":"

<\/p>\n

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae<\/sup> Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting<\/b><\/p>\n

Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR)<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Atara Biotherapeutics, Inc.<\/a> (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel\u00ae<\/sup>) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+<\/sup> PTLD) after hematopoietic cell transplantation (HCT). The results were featured in an oral presentation at the 47th<\/sup> Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021), taking place virtually from March 14 – 17, 2021.\n<\/p>\n

\nCombined analysis from these investigator-assessed studies demonstrates patients with EBV+ <\/sup>PTLD after HCT that is relapsed or refractory (R\/R) to rituximab who achieved either complete or partial response (CR or PR) after treatment with tab-cel\u00ae<\/sup> derived similar OS benefit. Treatment response and OS data were assessed from two completed single-arm, Phase 2 studies (NCT00002663<\/a>, NCT01498484<\/a>) and the multi\u2011center expanded access protocol (EAP-201) study (NCT02822495<\/a>).\n<\/p>\n

\n\u201cPatients who develop EBV+<\/sup> PTLD that is relapsed or refractory to rituximab after receiving hematopoietic cell transplant rapidly decline, with a median overall survival of only a few months,\u201d said Jakob Dupont, M.D., Head of Global Research & Development at Atara. \u201cTheir prognosis is poor and time is of the essence for this high-risk population. Data from across three clinical studies suggest that tab-cel\u00ae<\/sup> may provide an effective treatment option marked by long-term overall survival regardless of partial or complete response.\u201d\n<\/p>\n

\nAtara has previously shown clinical benefit in patients with EBV+<\/sup> PTLD after HCT who responded (CR or PR) to tab-cel\u00ae<\/sup> treatment, including an 86 percent two-year survival rate. Aggregated data presented at EBMT 2021 show patients who achieved a PR have similar one- and two-year probability of OS after tab-cel\u00ae<\/sup> treatment to those who achieved a CR. All patients received tab-cel\u00ae<\/sup> dose of 2×106<\/sup> cells\/kg on days 1, 8, and 15 in a 35-day treatment cycle. Patients received a median of two cycles (range, 1-5).\n<\/p>\n

\nThis data set included 50 HCT recipients who developed EBV+<\/sup> PTLD R\/R to rituximab that were treated with tab-cel\u00ae<\/sup>. Objective response rate (PR + CR) was 62 percent (31\/50) with best overall response (BOR) of CR (n=24) or PR (n=7). Similar one-year survival rates of 86.7 and 85.7 percent and two-year survival rates of 81.6 and 85.7 percent for patients with CR and PR, respectively were observed. Treatment was generally well-tolerated, with no confirmed evidence for graft-versus-host disease (GvHD), cytokine release syndrome (CRS) or neurotoxicity attributable to tab-cel\u00ae<\/sup>.\n<\/p>\n

\n\u201cWe are inspired by the consistency and clinical relevance of the tab-cel\u00ae<\/sup> data presented today, showing once again high overall response rates and favorable long-term survival in patients with EBV+<\/sup> PTLD following HCT,\u201d said Pascal Touchon, President and Chief Executive Officer of Atara. \u201cAtara is moving with a sense of urgency to serve these patients with high disease burden and unmet need, and is on track to complete a BLA filing in the U.S. for the PTLD indication in Q3 2021 as well as a MAA submission in Europe in Q4 2021.\u201d\n<\/p>\n

\nAtara also presented findings from a comprehensive multiomic analysis of modes of activation for tab-cel\u00ae<\/sup>. Each component of the assessment contributes to building the overall understanding of tab-cel\u2019s therapeutic activity, mechanisms of action and extended characteristics. Transcriptional data for tab-cel\u00ae<\/sup> demonstrate consistency of the product\u2019s activation profile irrespective of donor and consistent enrichment of receptors targeting EBV-driven diseases.\n<\/p>\n

Atara Presentations at EBMT 2021<\/span>:<\/b><\/p>\n

Title: <\/b>Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease after Allogeneic Hematopoietic Cell Transplant\n<\/p>\n

Date & Time: <\/b>Sunday, March 14, 2021; 08:30 a.m. \u2013 6:45 p.m. CET\/ 2:30 a.m. \u2013 12:45 p.m. EDT\n<\/p>\n

Oral session & Number:<\/b> Cellular Therapy, Gene Therapy and New Drugs II; 5\n<\/p>\n

Title: <\/b>Comprehensive Activation Profiling of Tabelecleucel, an Off-the-Shelf, Allogeneic EBV-specific T cell therapy (ENCORE FROM TCT 2021)\n<\/p>\n

Date & Time: <\/b>Available for viewing during poster sessions throughout the meeting\n<\/p>\n

Poster session & Number:<\/b> P031, Cellular Therapies other than CARs\n<\/p>\n

About Atara Biotherapeutics, Inc.<\/b><\/p>\n

Atara Biotherapeutics, Inc.<\/a>(@Atarabio)<\/a> is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel\u00ae<\/sup> in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+<\/sup> PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients\u2019 lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the potential benefits, safety and efficacy of tab-cel\u00ae<\/sup>; the timing and progress of tab-cel\u00ae<\/sup>, including data from tab-cel\u00ae<\/sup> clinical trials, the timing of the initiation or submission of the BLA [and MAA] for tab-cel\u00ae<\/sup>, Atara\u2019s ability to successfully advance the development of tab-cel\u00ae<\/sup>; and Atara\u2019s ability to advance development of its programs. Because such statements deal with future events and are based on Atara Biotherapeutics’ current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the ongoing COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara\u2019s cash resources and need for additional capital; and other risks and uncertainties affecting Atara\u2019s and its development programs, including those discussed in Atara Biotherapeutics’ filings with the Securities and Exchange Commission (SEC), including in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210314005028\/en\/<\/a><\/span><\/p>\n

INVESTORS & MEDIA:
\n
<\/b>
Media
\n<\/i><\/b>
Kerry Beth Daly
\n
Head, Corporate Communications
\n
Atara Biotherapeutics
\n
516-982-9328
\n
kdaly@atarabio.com
\n<\/a><\/p>\n

Investors
\n<\/i><\/b>
Eric Hyllengren
\n
Vice President, Investor Relations & Finance
\n
Atara Biotherapeutics
\n
805-395-9669
\n
ehyllengren@atarabio.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Hospitals Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel\u00ae) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell … <\/p>\n

Continue reading “Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457164","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAtara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel\u00ae) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell … Continue reading "Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:00:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting\",\"datePublished\":\"2021-03-15T11:00:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/\"},\"wordCount\":1379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/\",\"name\":\"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-15T11:00:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/","og_locale":"en_US","og_type":"article","og_title":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk","og_description":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel\u00ae) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell … Continue reading \"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:00:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting","datePublished":"2021-03-15T11:00:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/"},"wordCount":1379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/","name":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-15T11:00:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210314005028r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-presents-new-long-term-overall-survival-data-from-a-combined-analysis-of-phase-2-tab-cel-studies-for-epstein-barr-virus-driven-post-transplant-lymphoproliferative-disease-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel\u00ae Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457164"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457164\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}